Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432757 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
A Phase 3 study, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00432757 is a Phase 3 study that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT00432757, a Phase 3 study, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
Interventions
- DRUG Ketotifen with a Contact Lens (generic name not yet established)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00432757
The ClinicalTrials.gov registry entry for NCT00432757 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketotifen with a Contact Lens (generic name not yet established) is the first listed.
NCT00432757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00432757 about?
NCT00432757 is a clinical study titled "Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis". The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
What is the current status of trial NCT00432757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2007-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00432757?
The interventions under investigation include: Ketotifen with a Contact Lens (generic name not yet established) (DRUG).
Who is sponsoring clinical trial NCT00432757?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.